|Monday, 1 November 2021, 08:41 HKT/SGT|
TOKYO, Nov 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. and PRISM BioLab Co., Ltd. announced today that the CREB-binding protein (CBP) / beta-catenin inhibitor E7386, a medium-molecular weight compound created through collaboration research between Eisai and PRISM, has achieved the clinical POC (Proof of Concept).
Eisai is conducting a Phase I clinical study of E7386 monotherapy for solid tumors, and a Phase Ib clinical trial of E7386 plus lenvatinib mesylate (product name: LENVIMA, "lenvatinib"), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for solid tumors including hepatocellular carcinoma. The achievement of the POC, which is defined in a collaborative research agreement between Eisai and PRISM, was confirmed based on data such as antitumor activity and changes of biomarkers in these clinical trials.
The E7386 targets, beta-catenin, is considered to be one of the undruggable targets that are particularly difficult to develop into drug discovery. beta-catenin, along with CBP, which is also the target of E7386, is located at the downstream of the Wnt signaling and regulates the Wnt signaling-dependent transcription activity. E7386 is a CBP / beta-catenin inhibitor that inhibits CBP and beta-catenin protein-protein interactions and regulates the Wnt signal-dependent gene expression. It is expected to suppress tumor growth dependent on the Wnt signaling. 1 E7386 is also expected to release the suppression of tumor-infiltrating T cells by the Wnt signaling activation, and to enhance the effect of immune checkpoint inhibitors1. The antitumor effect of E7386 alone and the combination of E7386 and anti-PD-1 antibody has been confirmed in a cancer-bearing mouse model.(1)
Based on the POC achievement, Eisai has initiated a phase Ib/II clinical trial (Study 201) of E7386 in combination with anti-PD-1 therapy pembrolizumab for solid tumors in Japan.*
Dr. Takashi Owa, Senior Vice President, President of Oncology Business Group, at Eisai said, "With achieving the POC, we are confident with the prospect of offering E7386 to patients as a cancer treatment. E7386 may overcome lenvatinib and pembrolizumab treatment resistances through its combination therapy with lenvatinib or pembrolizumab. Eisai will accelerate clinical trials of E7386 in combination with lenvatinib or pembrolizumab, and do its utmost aiming to create new treatments for cancers with high unmet medical needs."
Dai Takehara, President and CEO of PRISM commented, "The approval of the clinical POC for the E7386 demonstrates that PRISM's drug discovery platform is an effective option for novel drug targets which have been considered difficult. We are grateful to Eisai for advancing this development. We will continue to take on the challenge of targeting more novel targets, with the aim of providing new treatment to as many patients as possible."
* Study 201 is being conducted under a clinical trial collaboration and supply agreement between Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A.
Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan, with approximately 10,000 employees worldwide. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. We strive to realize our hhc philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including Oncology and Neurology.
In the spirit of hhc, we take that commitment even further by applying our scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address society's toughest unmet needs, including neglected tropical diseases and the Sustainable Development Goals.
For further information on Eisai Co., Ltd., please visit https://www.eisai.com and connect with us on Twitter @Eisai_SDGs.
About PRISM BioLab
PRISM BioLab Co., Ltd., is a biotechnology company with proprietary small molecule drug discovery platform "PepMeticsTM Technology". The PepMeticsTM Molecules are designed to mimic alpha-helix or beta-turn peptide using a unique stable scaffold with corresponding dihedral angles. These motifs are essential for protein-protein interactions within the cell, especially related to transcription and translation. Using our small molecule drug discovery technology, two clinical-stage assets for cancer and fibrosis have been developed and licensed. Further, PRISM is working on new drug targets in collaboration with Global and Japanese pharmaceutical companies.
Wnt is a glycoprotein with a molecular weight of about 40,000, which is conserved across organisms from nematodes and Drosophila to mammals, and it is reported to control early development, morphogenesis, organogenesis, and cell proliferation, differentiation, and motility after birth. Pathways known to comprise the Wnt signaling pathway include the Wnt / beta-catenin pathway which is associated with cell differentiation and dorsal formation, the Wnt / PCP pathway which is involved in planar cell polarity and motility during gastrulation, the Wnt / Ca2+ pathway which plays a role in embryonic isolation and the pathway involved in the regulation of muscle regeneration. The most well-known Wnt signaling is the Wnt / beta-catenin pathway. It has been reported that beta-catenin induces gene expression as a mediator of Wnt signaling, and as a result regulates cell proliferation and differentiation. beta-catenin, along with RAS, P53 and MYC, is called "Cancer's Big 4" and is considered to be one of the undruggable targets that are difficult to develop into drug discovery.
E7386 is a CBP / beta-catenin inhibitor that inhibits protein-protein interactions between the transcription coactivator CBP and beta-catenin, and regulates the Wnt signaling-dependent gene expression. Since E7386 acts on the CBP / beta-catenin transcription complex located at the most downstream of the Wnt signaling, it is expected to inhibit not only ligand- dependent activation but also activation caused by gene mutations in Wnt signaling factors such as adenomatous polyposis coli (APC) and beta-catenin.
(1) Cancer Res. 2021 Feb 15;81(4):1052-1062.
Eisai Co., Ltd., Public Relations Department
PRISM BioLab Co., Ltd.
TEL: +81-(0) 466-53-8383
Topic: Press release summary
Sectors: BioTech, Clinical Trials
From the Asia Corporate News Network
Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|Jan 20, 2022 08:56 HKT/SGT|
Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma |
|Jan 19, 2022 16:36 HKT/SGT|
Eisai Listed as a Global 100 Most Sustainable Corporation for the Sixth Time|
|Jan 19, 2022 09:06 HKT/SGT|
Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study|
|Jan 17, 2022 10:44 HKT/SGT|
Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium|
|Jan 13, 2022 12:26 HKT/SGT|
Eisai to Launch Digital Too "Cogmate" in Taiwan and Hong Kong for Self-Assessment of Brain Performance (Brain Health)|
|Jan 6, 2022 10:09 HKT/SGT|
Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator|
|Dec 24, 2021 08:26 HKT/SGT|
Investigational Alzheimer's Disease Therapy Lecanemab Granted FDA Fast Track Designation|
|Dec 21, 2021 09:23 HKT/SGT|
Biogen Announces Reduced Price for Aduhelm to Improve Access For Patients With Early Alzheimer's Disease In The United States|
|Dec 20, 2021 12:35 HKT/SGT|
Eisai Enters into Commercialization and Distribution Agreement with Gilead for JAK Inhibitor Filgotinib in Asia|
|Dec 6, 2021 11:30 HKT/SGT|
Eisai to Present Abstracts on Oncology Products And Pipeline at 44th Annual San Antonio Breast Cancer Symposium|
|More news >>|